Target Validation Information
TTD ID T36059
Target Name Adenosine A3 receptor (ADORA3)
Type of Target
Clinical trial
Drug Potency against Target Adenosine Drug Info Ki = 290 nM [44]
Drug Info IC50 = 5 nM [14]
Drug Info IC50 = 613 nM [14]
(+)-BUTACLAMOL Drug Info IC50 = 8.9 nM [14]
1,2-dihydro-2-oxoquinazoline-4-carboxyanilide Drug Info IC50 = 238 nM [27]
1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea Drug Info Ki = 180 nM [18]
1-Allyl-3,7-dihydro-purine-2,6-dione Drug Info Ki = 16100 nM [5]
1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione Drug Info Ki = 370 nM [6]
1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione Drug Info Ki = 4440 nM [5]
1-Butyl-3,7-dihydro-purine-2,6-dione Drug Info Ki = 4.61 nM [5]
1-Cyclopentyl-3,7-dihydro-purine-2,6-dione Drug Info Ki = 639 nM [5]
1-Phenethyl-3,7-dihydro-purine-2,6-dione Drug Info Ki = 7510 nM [5]
1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea Drug Info Ki = 490 nM [18]
1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea Drug Info Ki = 51 nM [18]
1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea Drug Info Ki = 76 nM [18]
1-phenyl-3-(quinazolin-4-yl)urea Drug Info Ki = 1200 nM [18]
1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione Drug Info Ki = 3080 nM [5]
1-Propyl-3,7-dihydro-purine-2,6-dione Drug Info Ki = 2370 nM [5]
2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine Drug Info Ki = 417 nM [32]
2,6,8-triphenyl-9H-purine Drug Info Ki = 49 nM [17]
2,6-bis(4-chlorophenyl)-9H-purine Drug Info Ki = 68 nM [17]
2,6-bis(4-methoxyphenyl)-9H-purine Drug Info Ki = 165 nM [17]
2,6-bis(4-tolyl)-9H-purine Drug Info Ki = 9.3 nM [17]
2,6-diphenyl-1-deazapurine Drug Info Ki = 180 nM [21]
2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine Drug Info Ki = 171 nM [21]
2,6-diphenyl-8-ethyl-1-deazapurine Drug Info Ki = 8.5 nM [21]
2,6-diphenyl-8-methyl-1-deazapurine Drug Info Ki = 61 nM [21]
2,6-diphenyl-8-tButyl-1-deazapurine Drug Info Ki = 115 nM [21]
2,6-diphenyl-9H-purine Drug Info Ki = 38 nM [17]
2,6-dphenyl-8-propyl-1-deazapurine Drug Info Ki = 69 nM [21]
2-(1H-benzo[d]imidazol-2-yl)quinoxaline Drug Info Ki = 763 nM [29]
2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline Drug Info Ki = 168 nM [16]
2-(2''-indolylethyloxy)adenosine Drug Info Ki = 513 nM [23]
2-(3''(5''-chloro-indolyl)ethyloxy)adenosine Drug Info Ki = 296 nM [23]
2-(3''(7''-bromo-indolyl)ethyloxy)adenosine Drug Info Ki = 142 nM [23]
2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine Drug Info Ki = 260 nM [23]
2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine Drug Info Ki = 234 nM [23]
2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine Drug Info Ki = 490 nM [23]
2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine Drug Info Ki = 120 nM [23]
2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine Drug Info Ki = 110 nM [23]
2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine Drug Info Ki = 360 nM [23]
2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine Drug Info Ki = 90 nM [23]
2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine Drug Info Ki = 92.3 nM [23]
2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine Drug Info Ki = 2070 nM [23]
2-(3''-(benzotriazole-1''-yl)ethyloxy)adenosine Drug Info Ki = 1920 nM [23]
2-(3''-indolylethyloxy)adenosine Drug Info Ki = 232 nM [23]
2-(3''-pyrrolylethyloxy)adenosine Drug Info Ki = 104 nM [23]
2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline Drug Info Ki = 140 nM [16]
2-(4-chlorophenyl)-6-phenyl-9H-purine Drug Info Ki = 94 nM [17]
2-(4-ethylthiobenzimidazol-2-yl)quinoxaline Drug Info Ki = 955 nM [16]
2-(4-hydroxypent-1-yl)-N6-methoxyadenosine Drug Info Ki = 5.4 nM [22]
2-(4-methoxyphenyl)-6-phenyl-9H-purine Drug Info Ki = 4 nM [17]
2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline Drug Info Ki = 26 nM [29]
2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline Drug Info Ki = 879 nM [16]
2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline Drug Info Ki = 632 nM [16]
2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine Drug Info Ki = 4.1 nM [22]
2-(hex-1-ynyl)-N6-methoxyadenosine Drug Info Ki = 2.8 nM [22]
2-acetylaminoquinazoline-4-carboxyanilide Drug Info IC50 = 140 nM [27]
2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide Drug Info Ki = 550 nM [27]
2-aminoquinazoline-4-carboxyanilide Drug Info Ki = 350 nM [27]
2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine Drug Info Ki = 10.8 nM [20]
2-benzoylaminoquinazoline-4-carboxyanilide Drug Info Ki = 182 nM [27]
2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one Drug Info Ki = 74.5 nM [25]
2-chloro-2'-C-methyl-tecadenoson Drug Info Ki = 18900 nM [26]
2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine Drug Info Ki = 1813 nM [30]
2-ethynyl-N6-methoxyadenosine Drug Info Ki = 23 nM [22]
2-Phenyl-2H-pyrazolo[4,3-c]quinoline Drug Info Ki = 212 nM [13]
2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one Drug Info Ki = 725 nM [34]
2-phenylpropoxyadenosine Drug Info Ki = 66 nM [23]
2-tolyl-6-phenyl-9H-purine Drug Info Ki = 9.4 nM [17]
2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine Drug Info Ki = 3 nM [22]
2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine Drug Info Ki = 4.4 nM [22]
3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one Drug Info Ki = 125 nM [29]
3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione Drug Info Ki = 6880 nM [5]
3-noradamantyl-1,3-dipropylxanthine Drug Info Ki = 4390 nM [19]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info Ki < 1000 nM [38]
4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one Drug Info Ki = 12300 nM [43]
4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline Drug Info Ki = 166 nM [13]
4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide Drug Info Ki = 79 nM [3]
5,6,7-Trimethyl-2-p-tolyl-chromen-4-one Drug Info Ki = 4480 nM [42]
5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol Drug Info Ki = 2050 nM [28]
5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol Drug Info Ki = 262 nM [21]
5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine Drug Info IC50 = 0.25 nM [8]
6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine Drug Info Ki = 30 nM [23]
6-guanidino-2-(3''-indolylethyloxy)adenosine Drug Info Ki = 90 nM [23]
6-Hydroxy-5,7-dimethyl-beta-carboline Drug Info Ki = 17700 nM [28]
8-Bromo-9-(3-hydroxypropyl)-9H-adenine Drug Info Ki = 3200 nM [31]
8-Bromo-9-(sec-butyl)-9H-adenine Drug Info Ki = 15000 nM [31]
8-Bromo-9-cyclobutyl-9H-adenine Drug Info Ki = 6200 nM [31]
8-Bromo-9-cyclohexyl-9H-adenine Drug Info Ki = 11000 nM [31]
8-Bromo-9-cyclopentyl-9H-adenine Drug Info Ki = 4200 nM [31]
8-bromo-9-isobutyl-9H-purin-6-amine Drug Info Ki = 15000 nM [37]
8-Bromo-9-isopropyl-9H-adenine Drug Info Ki = 15000 nM [31]
8-Hydroxy-5,7,9-trimethyl-delta-carboline Drug Info Ki = 13300 nM [28]
8-Hydroxy-7,9-dimethyl-delta-carboline Drug Info Ki = 4430 nM [28]
8-PHENYL THEOPHYLLINE Drug Info Ki = 500 nM [41]
8-propyl-2,6-diphenyl-9H-purine Drug Info Ki = 17 nM [17]
9-Cyclopentyl-9H-adenine Drug Info Ki = 13000 nM [31]
9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine Drug Info Ki = 86 nM [4]
9H-purine derivative Drug Info IC50 = 14 nM [14]
BEMESETRON Drug Info IC50 = 9.3 nM [14]
CIRSIMARITIN Drug Info Ki = 1720 nM [42]
CVT-6883 Drug Info Ki = 1070 nM [33]
Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine Drug Info Ki = 47 nM [12]
Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine Drug Info Ki = 134 nM [12]
DIZOCILPINE Drug Info IC50 = 2 nM [14]
Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate Drug Info Ki = 206 nM [36]
flavone Drug Info Ki = 16900 nM [42]
Galangin Drug Info Ki = 3150 nM [42]
GNF-PF-2224 Drug Info Ki = 1300 nM [40]
GW-328267 Drug Info Ki = 92 nM [9]
Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide Drug Info Ki = 392 nM [10]
isobutylmethylxanthine Drug Info Ki = 50 nM [41]
L-249313 Drug Info Ki = 13 nM [2]
LUF-5417 Drug Info Ki = 82 nM [36]
LUF-5433 Drug Info Ki = 670 nM [36]
LUF-5767 Drug Info Ki = 147 nM [10]
LUF-5816 Drug Info Ki = 6.9 nM [21]
LUF-5956 Drug Info Ki = 9.5 nM [17]
LUF-5957 Drug Info Ki = 200 nM [17]
LUF-5962 Drug Info Ki = 35 nM [17]
LUF-5978 Drug Info Ki = 25 nM [21]
LUF-5980 Drug Info Ki = 7.3 nM [21]
LUF-5981 Drug Info Ki = 637 nM [21]
MESULERGINE Drug Info IC50 = 1.9 nM [14]
METHOCTRAMINE Drug Info IC50 = 34 nM [14]
METHYLTHIOADENOSINE Drug Info Ki = 680 nM [7]
METRIFUDIL Drug Info Ki = 47 nM [11]
MRS1041 Drug Info Ki = 18200 nM [43]
MRS928 Drug Info Ki = 1210 nM [42]
N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine Drug Info Ki = 920 nM [12]
N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine Drug Info Ki = 1120 nM [12]
N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine Drug Info Ki = 51 nM [12]
N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine Drug Info Ki = 340 nM [12]
N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide Drug Info Ki = 447 nM [10]
N-(2,6-diphenylpyrimidin-4-yl)acetamide Drug Info Ki = 6.88 nM [10]
N-(2,6-diphenylpyrimidin-4-yl)benzamide Drug Info Ki = 1300 nM [10]
N-(2,6-diphenylpyrimidin-4-yl)butyramide Drug Info Ki = 167 nM [10]
N-(2,6-diphenylpyrimidin-4-yl)isobutyramide Drug Info Ki = 267 nM [10]
N-(2,6-diphenylpyrimidin-4-yl)propionamide Drug Info Ki = 22.4 nM [10]
N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide Drug Info Ki = 333 nM [35]
N-(4,5-diphenylpyrimidin-2-yl)acetamide Drug Info Ki = 237 nM [10]
N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide Drug Info Ki = 3280 nM [10]
N-(4,6-diphenylpyrimidin-2-yl)propionamide Drug Info Ki = 547 nM [10]
N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide Drug Info Ki = 354 nM [36]
N6-((+/-)-endo-norborn-2-yl)adenosine Drug Info Ki = 101 nM [32]
N6-(3-Iodobenzyl)-2'-O-methyladenosine Drug Info IC50 = 1.7 nM [24]
N6-CYCLOPENTYLADENOSINE Drug Info Ki = 97 nM [15]
N6-methoxy-2-phenylethynyladenosine Drug Info Ki = 3.8 nM [22]
N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine Drug Info Ki = 2.3 nM [22]
N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine Drug Info Ki = 7.9 nM [22]
N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine Drug Info Ki = 4.3 nM [22]
N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine Drug Info Ki = 5.9 nM [22]
N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine Drug Info Ki = 39 nM [22]
N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine Drug Info Ki = 6 nM [22]
N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine Drug Info Ki = 13 nM [22]
NIPECOTIC ACID Drug Info IC50 = 10.1 nM [14]
NITD609 Drug Info IC50 = 8300 nM [39]
NSC-407228 Drug Info Ki = 3400 nM [42]
R-N6-(phenylisopropyl)adenosine Drug Info Ki = 8.7 nM [23]
REVERSINE Drug Info Ki = 660 nM [12]
SB-298 Drug Info Ki = 422 nM [33]
SEROTONIN Drug Info IC50 = 79 nM [14]
Tonapofylline Drug Info Ki = 10000 nM [36]
VUF-8504 Drug Info Ki = 17 nM [18]
VUF-8507 Drug Info Ki = 200 nM [18]
[3H]CCPA Drug Info Ki = 18800 nM [26]
[3H]kainate Drug Info IC50 = 77 nM [14]
[3H]NECA Drug Info Ki = 113 nM [1]
[3H]OSIP339391 Drug Info Ki = 450 nM [37]
References
REF 1 5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors. J Med Chem. 1999 Apr 22;42(8):1384-92.
REF 2 The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. Bioorg Med Chem Lett. 2000 Jan 3;10(1):31-4.
REF 3 Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9.
REF 4 Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1931-4.
REF 5 Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8.
REF 6 Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3337-44.
REF 7 Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
REF 8 Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands. Bioorg Med Chem Lett. 2004 May 17;14(10):2443-6.
REF 9 Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor. J Med Chem. 2004 Jul 29;47(16):4041-53.
REF 10 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40.
REF 11 (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem. 2005 Mar 24;48(6):1745-58.
REF 12 Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
REF 13 New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):5001-8.
REF 14 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
REF 15 Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprote... J Med Chem. 2005 Dec 29;48(26):8103-7.
REF 16 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60.
REF 17 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7.
REF 18 Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97.
REF 19 Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31.
REF 20 2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem. 2006 Dec 14;49(25):7373-83.
REF 21 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34.
REF 22 N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
REF 23 Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27.
REF 24 Design, synthesis, and biological evaluation of LNA nucleosides as adenosine A3 receptor ligands. Bioorg Med Chem. 2007 Aug 15;15(16):5440-7.
REF 25 New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74.
REF 26 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
REF 27 Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606.
REF 28 Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30.
REF 29 Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70.
REF 30 Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3.
REF 31 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
REF 32 N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406.
REF 33 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006.
REF 34 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52.
REF 35 Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700.
REF 36 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
REF 37 Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71.
REF 38 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
REF 39 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
REF 40 Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands. Bioorg Med Chem. 2010 Nov 15;18(22):7890-9.
REF 41 Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207.
REF 42 Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8.
REF 43 Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
REF 44 Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem. 2003;3(4):445-62.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.